Health Catalyst (HCAT) Misses Q3 EPS by 3c, provides guidance

Health Catalyst (NASDAQ: HCAT) reported Q3 EPS of $0.07, $0.03 worse than the analyst estimate of $0.10. Revenue for the quarter came in at $76.4 million versus the consensus estimate of $76.27 million.

GUIDANCE:

Health Catalyst sees Q4 2024 revenue of $78-84 million, versus the consensus of $80.656 million. Adjusted EBITDA between $6.8 million and $8.8 million

For the full year of 2024, we expect:

Total revenue between $305.0 million and $311.0 million, versus the consensus of $342.4

Adjusted EBITDA between $25.0 million and $27.0 million

For earnings history and earnings-related data on Health Catalyst (HCAT) click here.

You May Also Be Interested In

• Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
• Therma Bright plans $420,000 non-brokered private placement
• Meta's Muse AI to counter China models with subscribers, not ads, Alexandr Wang says - Nikkei